This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease

Tuesday, October 25, 2016

Submitted by


Source Name: Journal of Thoracic and Cardiovascular Surgery


Rio Nomoto, Lynn A. Sleeper, Michele J. Borisuk, Lisa Bergerson, Frank A. Pigula, Sitaram Emani, Francis Fynn-Thompson, John E. Mayer, Pedro J. del Nido, Christopher W. Baird

This single center review assessed the need for reintervention after pulmonary valve replacement with bioprostheses for congenital heart disease.  Most patients had TOF, and most were in their teens or twenties.  After correction for age, the Sorin Mitroflow valve required reintervention sooner and more often than the other two valves (Carpentier-Edwards Magna and MagnaEase, Carpentier-Edwards Perimount).  Valve type was the only independent predictor of reintervention. 

See also: Pulmonary valve replacement for congenital heart disease: What valve substitute should we be using?

Add comment

Log in or register to post comments